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Long-acting injectable versus daily oral antipsychotic
treatment trials in schizophrenia: pragmatic versus
explanatory study designs
Cynthia A. Bossiea, Larry D. Alphsa and Christoph U. Correllb,c
Trial design characteristics related to the
explanatory : pragmatic spectrummay contribute toward the
inconsistent results reported in studies comparing long-
acting injectable (LAI) versus daily oral antipsychotic (AP)
treatments in schizophrenia. A novel approach examined
the hypothesis that a more pragmatic design is important
to show the advantages of LAI versus oral APs. A literature
search identified comparative studies assessing the clinical
efficacy/effectiveness of LAI versus oral APs in more than
100 schizophrenia patients, with 6-month or more
duration/follow-up, and published between January 1993
and December 2013 (n= 11). Each study’s design was rated
using the six-domain ASPECT-R (A Study
Pragmatic : Explanatory Characterization Tool-Rating).
Nonparametric Wilcoxon rank-sum tests compared ratings
of studies supporting (n= 7) and not supporting (n= 4) a
LAI advantage. ASPECT-R total and domain scores were
significantly higher (more pragmatic) in studies finding a
LAI versus oral AP treatment advantage than those that did
not. The rank order of this significance among domains was
as follows: ‘participant compliance assessment’ (P= 0.005),
‘medical practice setting/practitioner expertise’ (P= 0.006),
‘intervention flexibility’ (P= 0.007), ‘follow-up intensity/
duration’ (P= 0.009), ‘primary trial outcomes’ (P= 0.012),
and ‘participant eligibility’ (P= 0.015). Findings support that
more pragmatic, less explanatory design features are
important to show advantages for LAI treatment.
Explanatory studies may introduce features that obscure
advantages related to adherence. Int Clin Psychopharmacol
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Introduction
Schizophrenia has remained a chronic and often severely
impairing mental disorder despite the development of
effective antipsychotic (AP) treatments. One of the rea-
sons for relapses is nonadherence with prescribed treat-
ment (Kane et al., 2013a). To improve treatment
adherence and outcomes, long-acting injectable (LAI)
formulations of APs have been developed. The potential
benefit of treatment delivered as a LAI versus a daily
orally administered AP agent lies in advantages asso-
ciated with removing the need for daily medication
administration and signaling the clinician when non-
adherence occurs. Treatment discontinuations (Zipursky
et al., 2014) and intermittent treatment (Sampson et al.,
2013) have been associated with increased relapses.
Treatment with LAIs should increase the likelihood of
continuous effective exposure over extended periods. An
increasing number of published studies have compared
the effects of LAI and oral APs in patients with schizo-
phrenia. On the basis of the association between non-
adherence and relapse, these studies hypothesized an
advantage for the LAI treatment. Although mirror-image
studies, which arguably include more broadly repre-
sentative patient populations, have reported advantages
on the basis of this difference in modality (Kishimoto
et al., 2013), randomized-controlled trials have frequently
failed to show advantages (Fusar-Poli et al., 2013; Kirson
et al., 2013; Kishimoto et al., 2014; Buckley et al., 2015).
Although highly controlled studies are the gold standard
to address many clinical research questions, we believe
that more pragmatic approaches are required to address
questions associated with adherence. Pragmatic (often
referred to as effectiveness) studies aim for a high degree
of external validity, seeking to answer whether an inter-
vention works under usual clinical or ‘real-world’ condi-
tions. In contrast, explanatory (often referred to as
efficacy) studies aim for a high degree of internal validity,
exploring whether an intervention works under more
constrained conditions. To achieve this goal, explanatory
trials are conducted under highly controlled and well-
defined treatment conditions, which are necessary to
minimize ambiguity and address the primary questions
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for which this type of trial is designed. They typically
include populations that do not reflect the full clinical
population in which the intervention will be used.
Design elements inherent to explanatory trials may
obscure factors that drive the advantage of certain treat-
ment approaches. This is particularly true for studies that
address the common issue of nonadherence. For exam-
ple, the clinical advantage of ensured longer exposure to
therapeutic doses with long-acting formulations of AP
medications compared with oral formulations may not be
evident in an explanatory trial that strongly reinforces
adherence. Other explanatory design features that may
obscure differences that occur under real-world condi-
tions may include the frequent use of extensive but
burdensome healthcare assessments, exceptionally close
follow-up and reconnection with the patient, and finan-
cial incentives for patient participation. In addition,
selection bias may result from the enrollment of partici-
pants in clinical trials who tend to be more adherent to
research procedures. Individuals with less severe illness
and greater insight into their illness may also be more
likely to adhere to their assigned treatment regimen
(Kane et al., 2013b).
Understanding the inconsistent body of literature comparing
LAI and daily oral APs has been the focus of several recent
publications. Although an earlier meta-analysis found a sig-
nificant benefit of LAI versus daily oral APs (Leucht et al.,
2011), two larger and more recent meta-analyses of
randomized-controlled trials concluded that there is no
advantage for LAI formulations in preventing relapse and
hospitalization (Fusar-Poli et al., 2013; Kishimoto et al., 2014).
The focus of these analyses on controlled, randomized stu-
dies likely resulted in a bias toward inclusion of highly
explanatory trials. Some authors note that their findings
contrast with those of recent naturalistic mirror-image and
cohort studies, and suggest that pragmatic trial designs be
utilized in future research to be more reflective of actual
clinical care received by patients with schizophrenia (Kane
et al., 2013b; Kishimoto et al., 2014; Buckley et al., 2015). In
particular, these authors expressed concern that patients
undergoing intensive consent and assessment procedures
may be more adherent and less severely ill than those
encountered in everyday practice. Consequently, they sug-
gest that using a LAI AP formulation in a naturalistic setting
might confer additional benefit over the corresponding daily
oral formulation (Kane et al., 2013a). Supporting this con-
sideration, in randomized-controlled trials where adherence
was formally assessed, no differences were observed in
adherence between LAI and daily oral AP formulations
(Leucht et al., 2011; Kishimoto et al., 2014).
Recently, a meta-analysis by Kirson et al. (2013) was
published that included studies of varying designs
(randomized-controlled, prospective observational, and
retrospective observational trials). These authors repor-
ted significant advantages for LAI treatments studied in
trials with observational designs, but not in those with
randomized-controlled designs. These conclusions are
supported in a recent meta-analysis by Kishimoto et al.
(2013) with 25 mirror-image studies in which 22 showed
significant advantages of the LAI versus daily oral AP
treatment for preventing psychiatric hospitalization.
However, the authors acknowledge that mirror-image
studies can also be biased by the fact that treatment
status is not blinded, thresholds for hospitalization can
change over time, and that LAIs are always started after
suboptimal outcomes on daily oral APs. They also note
that reverse mirror-image studies (i.e. from LAI to oral
formulation) are lacking.
None of these meta-analyses used a formalized measure
of the explanatory or the pragmatic nature of specific trial
design features. In practice, most trial designs are neither
purely explanatory nor purely pragmatic. Instead, most
lie along a continuum between these two extremes. The
research reported here uses a novel approach for quan-
tifying an individual study’s design along this continuum
and examines the hypothesis that a more pragmatic
design is important for showing advantages for LAI ver-
sus daily oral AP treatment.
Methods
Literature review
The objective of this review was to identify comparative
studies of the clinical efficacy of LAI versus daily oral
APs. Selection criteria included studies published from
1993 to 2013, whose duration was 6 months or longer, and
that had enrolled at least 100 patients with a diagnosis of
schizophrenia. The publication period reflects a time
when clinical trial designs were likely to be better
described and when treatment modalities that are
reflective of current realities were studied. The require-
ment for a 6-month or longer duration of follow-up was
imposed to provide an adequate period for observing
potential differences between long-acting and daily oral
AP treatments. The 100-patient enrollment criterion was
incorporated to increase the likelihood that the study
would be sufficiently powered to detect meaningful dif-
ferences between treatments.
This literature review consisted of three components: (i) a
search engine-based literature review; (ii) an examination of
relevant review articles; and (iii) any other published studies
known to the authors (Fig. 1). The literature search was
performed using MEDLINE/PubMed. Search terms and
criteria were as follows: (((Antipsychotic) AND schizo-
phrenia) AND ((depot OR injection OR long-acting))) AND
oral. Filters included clinical trial, human, English language,
and publication dates of 1 January 1993 to 31 December
2013. The manual review of citations identified by
MEDLINE/PubMed removed those that: (i) did not
include both a LAI and an oral AP treatment arm; (ii) did not
include a measure of clinical efficacy or effectiveness;
(iii) represented findings from a pooled analysis (vs. a single
study); (iv) had a duration of less than 6 months; (v) enrolled
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less than 100 participants; (vi) were not in English; and (vii)
were a secondary publication of a previously included study
(i.e. post-hoc subpopulation data). This literature search was
then supplemented by an examination of references cited in
relevant review articles and any other published studies
known to the authors through December 2013.
ASPECT-R, the tool
‘A Study Pragmatic : Explanatory Characterization Tool-
Rating’ or ASPECT-R ((c) 2014 Janssen Pharmaceuticals,
Inc., Titusville, New Jersey, USA) is a tool informed by the
PRECIS tool (Thorpe et al., 2009; Tosh et al., 2011) that
characterizes the explanatory : pragmatic nature of a study’s
design (L.D. Alphs and C.A. Bossie, 2015, submitted).
ASPECT-R considers six study design domains important
to the conduct of clinical trials along the explanatory :
pragmatic spectrum: (i) participant eligibility criteria; (ii)
intervention flexibility; (iii) medical practice setting/practi-
tioner expertise; (iv) follow-up intensity/duration; (v) pri-
mary trial outcomes; and (vi) participant compliance
assessment. Each domain is rated using a detailed anchored
seven-point scale where 0=extremely explanatory; 1=very
explanatory; 2=explanatory; 3=elements of both designs;
4=pragmatic; 5=very pragmatic; and 6= extremely
Fig. 1
Records identified through 
MEDLINE/PubMed database searching 
using criteria: (((Antipsychotic) AND 
schizophrenia) AND ((depot OR 
injection OR long-acting))) AND oral. 
Filters were: clinical trial, human, 
English language, and dates of 1 January
1993 to 31 December 2013
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Title and abstract review of 130 citations
Review of reference lists of 4 
meta-analyses (Leucht et al., 
2011; Fusar-Poli et al., 2013; 
Kirson et al., 2013; Kishimoto 
et al., 2014) for additional potential
citations
n=3 citations  
Not a single study (i.e. pooled analysis) (n=2)
Trial <6 months in duration (n=6)
Author (C.A.B.) identified 
an additional published 
study through regular 
reading of literature
n=1 citation
Studies included and rated using ASPECT-R:
n=11 studies; total of 21 159 participants
7 from MEDLINE/PubMed:
[Keks et al., 2007; Zhu et al., 2008 (methods described in Ascher-Svanum et al., 2006); Olivares et al.,
2009; Gaebel et al., 2010; Kane et al., 2010; Rosenheck et al., 2011; Tiihonen et al., 2011)
3 from reference list review:
(Tiihonen et al., 2006; Macfadden et al., 2010; Grimaldi-Bensouda et al., 2012)
1 from literature reading:
(Bitter et al., 2013)
4 studies demonstrating no difference 
between LAI and oral antipsychotics:
2330 participants (range 349—1065)
7 studies demonstrating a difference 
between LAI and oral antipsychotics:
18 829 participants (range 297—9567)
Citations removed (N=119) and reason: 
Lack of LAI and oral AP arm or LAI vs. oral AP comparison(n=76)
No assessment of clinical efficacy/effectiveness (n=17)
Included <100 patients (n=14)
Not in English (n=1)
Another citation from a previously identified study (n=3)
n=126 citations 
Flow chart of identification, screening and eligibility, and inclusion of clinical trials. AP, antipsychotic; LAI, long-acting injectable.
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Table 1 Study design features and main findings by outcome grouping
References Study design Findings
Studies concluding a benefit for a LAI compared with a daily oral AP
Bitter et al. (2013) Design: Observational, 12-month follow-up study
Population: All patients in Hungary with schizophrenia or related
disorder between 1 July 2007 and 30 June 2008
Treatments: Started a new second-generation AP as
monotherapy (one depot formulation [RLAI] or one of 7 oral
APs)
Endpoint: Time to all-cause discontinuation
Population: N=9567
Time to discontinuation:
RLAI: median 215 days (95% CI 181–242; significantly
longer compared with oral APs)
Oral AP: medians ranged from 55 to 136 days
Grimaldi-Bensouda et al. (2012) Design: Prospective, observational, cohort evaluation, 12-month
follow-up
Population: Patients with schizophrenia hospitalized<93 days
from 177 public and private hospitals across France
Treatments: RLAI or other agents (non-RLAI)
Endpoints: Hospitalization (defined as full-time hospital stay in a
psychiatric ward or for psychiatric reasons) during 12 months
of follow-up
Population: N=1859
Hospitalization HR:
RLAI use vs. oral AP alone:
HR 0.66 (95% CI 0.44–1.01), all
HR 0.49 (95% CI 0.28–0.85), monotherapy
RLAI use vs. 1st-generation AP alone:
HR 0.58 (95% CI 0.36–0.94), all
HR 0.41 (95% CI 0.23–0.75), monotherapy
RLAI use vs. oral 2nd-generation AP:
HR 0.60 (95% CI 0.39–0.92), all
HR 0.51 (95% CI 0.29–0.91) monotherapy
Tiihonen et al. (2011) Design: Retrospective, register-based case linkage of national
databases, follow-up initiated at first hospitalization discharge
until 31 December 2007
Population: People in Finland with first hospitalization of
schizophrenia 2000–2007, without AP prescription within the
previous 6 months
Treatments: Depot APs (LAI) vs. oral equivalents
Endpoint: Rehospitalization for schizophrenia; risk of all-cause
discontinuation of initial AP medication
Population: N=2588
Rehospitalization:
HR 0.36 (95% CI 0.17–0.75, P=0.007); 64% lower risk
with any LAI vs. equivalent oral AP formulation
All-cause discontinuation:
HR 0.41 (95% CI 0.27–0.61, P<0.0001); 59% lower risk
with any LAI vs. equivalent oral AP formulation
Gaebel et al. (2010) Design: Open-label, randomized, active controlled, 2-year
evaluation
Population: Schizophrenia or related disorders, stable treatment
with oral risperidone, olanzapine, or conventional neuroleptics
Treatments: Switch to RLAI or oral quetiapine
Endpoint: Relapse
Population: N=666 evaluable (329 RLAI, 337 quetiapine)
Time to relapse: Significantly longer with RLAI vs. quetiapine
(P<0.0001)
Relapse risk: Significantly lower with RLAI vs. quetiapine;
HR 0.46 (97% CI 0.32–0.67)
Relapse rates: 16.5% RLAI and 31.3% quetiapine
Olivares et al. (2009) Design: Prospective, observational, 2-year follow-up
Population: Inpatients or outpatients in Spain with schizophrenia
Treatment: Initiated with or switched to RLAI or oral AP
Endpoints (at 24 months): Treatment retention, CGI-S scale, and
hospitalization stays/days
Population: N=1622 (1345 RLAI, 277 oral AP)
Treatment retention: RLAI 81.8% vs. 63.4% oral AP
(P<0.0001)
CGI-S score: RLAI −1.14 vs. −0.94 oral AP (P=0.0165)
Hospitalization stays (per-patient compared with preswitch):
RLAI −0.37 vs. −0.20 oral AP (P<0.05)
Hospitalization days (per-patient vs. preswitch): RLAI −18.7
vs. −13.0 oral AP (P<0.01)
Zhu et al. (2008) (methods described
in Ascher-Svanum et al., 2006)
Design: Prospective, nonrandomized, noninterventional, 3-year
trial
Population: Patients with schizophrenia, schizoaffective, or
schizophreniform disorders
Treatment: Initiated on AP (fluphenazine or haloperidol) in oral or
depot (LAI) formulation
Endpoints: Time to discontinuation and likelihood to stay on
medication
Population: N=299 (202 oral AP; 97 depot AP)
Time to discontinuation (mean±SD):
Fluphenazine: depot 292 ±106 days vs. oral 270 ±108 days
(P<0.01)
Haloperidol: depot 316 ±93 vs. oral 257 ±115 days
(P<0.01)
Likelihood to remain on medication-depot vs. oral AP:
HR 1.94 [95% CI 1.3–2.9; P<0.001 (log-rank), P=0.002
(Cox model)]
Tiihonen et al. (2006) Design: Prospective, cohort
Population: People in Finland with first hospitalization of
schizophrenia or schizoaffective disorder between January
1995 and December 2001
Treatment: Oral or depot AP agents
Endpoints: RR of rehospitalization and discontinuation with
monotherapy, with haloperidol-treated patients considered the
reference group
Population: N=2230
Rehospitalization: LAI perphenazine (RR 0.32; 95% CI
0.22–0.49) compared with oral haloperidol (RR 1.00;
95% CI 1.00)
Discontinuation: LAI perphenazine (RR 0.24; 95% CI
0.13–0.47) compared with oral haloperidol (RR 1.00;
95% CI 1.00)
Studies concluding no benefit for LAI compared with oral AP treatment
Rosenheck et al. (2011) Design: Randomized, prospective, 2-year follow-up
Population: Veterans affairs patients with schizophrenia or
schizoaffective disorder hospitalized within the previous 2 years
or at imminent risk for hospitalization
Treatments: RLAI or psychiatrist’s choice oral AP
Endpoint: Psychiatric hospitalization
Population: N=369; 40% hospitalized at randomization;
55% hospitalized within the previous 2 years and 5% at
risk for hospitalization
Rate of hospitalization: RLAI 39% (mean follow-up
10.8 months) vs. oral AP 45% (mean follow-up
11.3 months)
Time to hospitalization: No difference between RLAI and oral
AP arms; HR 0.87 (95% CI 0.63–1.20; P=0.39)
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pragmatic. Specific descriptive anchors for each of the seven
ratings are provided for each of the six domains.
The interclass correlation of the ASPECT-R total score is
0.87 (C.A. Bossie, L.D. Alphs, D. Williamson, L. Mao, C.
Kurut, the ASPECT-R Rater Team, 2015, submitted),
which corresponds to an excellent inter-rater reliability
(Cicchetti, 1994). The domains included in ASPECT-R
are generally accepted trial design elements relevant for
distinguishing pragmatic and explanatory trials, as evi-
denced by peer-reviewed publications (Thorpe et al.,
2009; Tosh et al., 2011; Lurie and Morgan, 2013; Roche
et al., 2013; Alphs et al., 2014; Sedgwick, 2014), which
lend support for the face validity of ASPECT-R.
ASPECT-R ratings
Full references of the studies identified were used as the
source information for rating the study designs with the
ASPECT-R tool. Two of the authors (C.A.B. and L.D.A.)
independently rated each of the studies identified by the
literature review using the ASPECT-R and then com-
pared their ratings. Differences in domain ratings were
resolved through a consensus rating process. The basis of
the consensus ratings for each domain for each study was
documented.
Illustrating ASPECT-R ratings relative to study results
ASPECT-R consensus ratings for each study were plot-
ted using radar graphs.
Statistical analysis
Studies were then categorized according to the outcome
as reported in the original publication, yielding two
groups: those showing an advantage for LAI over daily
oral AP treatment and those not showing such an
advantage. Total and domain ASPECT-R scores were
compared across the two groups of studies using the
nonparametric Wilcoxon rank-sum test to address the
non-normal distribution of the scores. Data were ana-
lyzed in JMP5 (5.0.1, 1989–2003; SAS Institute Inc.,
Cary, North Carolina, USA). All tests were two-sided and
α was set at 0.05. No adjustment was made for
multiplicity.
Results
Citation review and selection
Using the literature search terms and criteria summarized
above, a total of 126 citations were identified through the
MEDLINE/PubMed literature search. Three additional
citations were identified through manual review of the
reference lists of four meta-analyses (Leucht et al., 2011;
Fusar-Poli et al., 2013; Kirson et al., 2013; Kishimoto et al.,
2014). An additional citation (Bitter et al., 2013) was
identified through one author’s (C.A.B.) general knowl-
edge of the literature. Thus, a total of 130 citations were
identified (Fig. 1).
One author (C.A.B.) and another contributor (S.R. in
acknowledgments) reviewed the titles, abstracts, and full
publication of these articles for compliance with search
Table 1 (continued)
References Study design Findings
Kane et al. (2010) Design: Randomized, multicenter, 4–8-week open-label
conversion/stabilization phase, followed by up to a 24-week
double-blind maintenance phase
Population: Outpatients with schizophrenia stabilized on oral
olanzapine
Treatments: Switch to olanzapine LAI or maintain a stabilized
dose of oral olanzapine
Endpoints: Percentage of exacerbation-free patients and time to
relapse
Population: N=1065 (743 olanzapine LAI, 322 oral)
Exacerbation-free (at week 24):
Not significantly different between oral olanzapine (93%)
and LAI every 2- and 4-week regimens:
300 mg every 2 weeks: 95% (high-dose)
405 mg every 4 weeks: 90% (medium dose)
150 mg every 2 weeks: 84% (low dose)
45 mg every 4 weeks: 69% (very low dose)
Time to relapse:
No significant difference between high-dose or medium-
dose LAI and oral AP treatment (P≥0.21). Significantly
shorter with low-dose or very low-dose LAI compared with
oral AP (P≤0.004)
Macfadden et al. (2010) Design: Open-label, rater-blinded, randomized, multicenter,
2-year study
Population: Schizophrenia, not adequately treated, with 2 or more
hospitalizations in past year
Treatment: RLAI or oral aripiprazole
Endpoint: Relapse and remission
Population: N=349 (177 RLAI; 172 aripiprazole)
Time to relapse: Not significantly different between RLAI and
oral aripiprazole (P=0.684)
Time in remission: Not significantly different between RLAI
and oral aripiprazole, mean (SD) (days): 373.5 (282.6)
vs. 356.7 (292.0); P=0.646
Keks et al. (2007) Design: Open-label, randomized, multinational 12-month study
Population: Patients with schizophrenia or schizoaffective
disorder
Treatments: RLAI or oral olanzapine
Endpoints: PANSS, clinical improvement (≥20% reduction in
PANSS total), time to first deterioration (among those stabilized
at week 13) at month 12
Population: N=547 (247 RLAI; 300 oral olanzapine)
PANSS change score: No significant difference between
groups
Clinical improvement: RLAI 91% vs. 79% oral AP
(P<0.001)
Time to first deterioration: Comparable between groups
(HR 1.37, 95% CI 0.47–3.99)
AP, antipsychotic; CGI-S, Clinical Global Impression-Severity; CI, confidence interval; HR, hazard ratio; LAI, long-acting injectable; PANSS, Positive and Negative
Syndrome Scale; R, risperidone; RLAI, risperidone long-acting injectable; RR, relative risk.
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criteria and appropriateness of filters. A total of 119
citations were excluded as they did not fulfill the criteria
as described in Fig. 1. The remaining 11 study citations
(N= 21 159 participants) included: Zhu et al. (2008),
Olivares et al. (2009), Gaebel et al. (2010), Kane et al.
(2010), Macfadden et al. (2010), Tiihonen et al. (2011),
Rosenheck et al. (2011), Grimaldi-Bensouda et al. (2012),
Bitter et al. (2013) (methods described in Ascher-Svanum
et al., 2006), Keks et al. (2007), and Tiihonen et al. (2006).
Study design features and main findings for these 11
studies are summarized in Table 1. The 11 studies were
placed into two groups: those that showed a difference
between LAI and daily oral AP treatments [seven
studies, 18 829 participants (range 297–9567)] and those
that did not [four studies, studies, 2330 participants
(range 349–1065)].
Consensus ratings
ASPECT-R ratings of the seven studies concluding a
benefit of LAI versus daily oral APs are shown in Fig. 2.
Ratings of the four studies concluding no LAI versus
daily oral AP difference are shown in Fig. 3. Total
ASPECT-R scores (maximum possible score= 36) ran-
ged from 18 to 36 in the former group of studies and from
9 to 13 in the latter group (Table 2).
Fig. 2
Medical practice
setting/practitioner expertise —
experimental and comparision
Participant eligibility criteria
Participant 
compliance
Primary trial
outcomes
Follow-up
Intensity / duration
Intervention
flexibility —
experimental
and comparison
Increasingly
pragmatic
0
0 to 6 ASPECT-R rating scale where:
0=extremely explanatory
1= very explanatory
2=explanatory
4=pragmatic
5= very pragmatic
6=extremely pragmatic
3=elements of both designs
1 2 3 4 5 6
Bitter et al., 2013
Tiihonen et al., 2011
Gaebel et al., 2010
Olivares et al., 2009
Zhu et al., 2008
Tiihonen et al., 2006
Grimaldi-Bensouda et al., 2012
ASPECT-R ratings for the seven studies that concluded an advantage of long-acting injectable versus oral daily antipsychotic treatment in patients
with schizophrenia. ASPECT-R, A Study Pragmatic : Explanatory Characterization Tool-Rating.
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In five of the seven studies concluding a benefit of LAI
compared with daily oral AP treatment, all domains were
rated as more pragmatic (i.e. ASPECT-R ratings of 4, 5,
or 6; Tiihonen et al., 2006; Zhu et al., 2008; Olivares et al.,
2009; Tiihonen et al., 2011; Bitter et al., 2013). In one
study, most domains were rated as more pragmatic
(Grimaldi-Bensouda et al., 2012). In one study, domains
were variously characterized as more pragmatic or more
explanatory (Gaebel et al., 2010).
In three of the four studies concluding no benefit for LAI
compared with daily oral AP treatment, most domains were
rated as more explanatory (i.e. ASPECT-R rating of 0, 1, or
2; Keks et al., 2007; Kane et al., 2010; Macfadden et al., 2010).
In one study, domains were variously characterized as more
pragmatic or more explanatory (Rosenheck et al., 2011).
The mean ASPECT-R total score and individual domain
scores were significantly higher (more pragmatic) in the
seven studies finding an advantage of LAIs over daily oral
APs compared with the four studies that did not (Table 2).
The rank order of greatest significant differences in the six
domains between the two groups of studies was as follows:
‘participant compliance assessment’ (P= 0.005), ‘medical
practice setting/practitioner expertise’ (P= 0.006), ‘inter-
vention flexibility’ (P= 0.007), ‘follow-up intensity/dura-
tion’ (P= 0.009), ‘primary trial outcomes’ (P= 0.012), and
‘participant eligibility’ (P= 0.015).
Fig. 3
Intervention
flexibility –
experimental
and comparison
Increasingly
pragmatic
Medical practice
setting/practitioner expertise –
experimental and comparision
Follow-up
Intensity / duration
Participant eligibility criteria
Participant 
compliance
Primary trial
outcomes
Rosenheck et al., 2011
Macfadden et al., 2010
Kane et al., 2010
Keks et al., 2007
0 to 6 ASPECT-R rating scale where:
0=extremely explanatory
1= very explanatory
2=explanatory
4=pragmatic
5= very pragmatic
6=extremely pragmatic
3=elements of both designs
0 1 2 3 4 5 6
ASPECT-R ratings for the four studies that concluded no advantage for a long-acting injectable versus oral daily antipsychotic treatment in patients
with schizophrenia. ASPECT-R, A Study Pragmatic : Explanatory Characterization Tool-Rating.
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Discussion
A novel quantitative approach was used to examine the
hypothesis that a more pragmatic study design is impor-
tant for showing the advantages of LAI over oral AP
treatment for patients with schizophrenia who are fre-
quently nonadherent, increasing the risk of relapse.
Theoretical advantages of LAIs are associated with
removing the need for daily adherence. Several meta-
analytic approaches have been used to examine this
question, with mixed conclusions (Leucht et al., 2011;
Fusar-Poli et al., 2013; Kirson et al., 2013; Kishimoto et al.,
2014). This report describes the application of a new tool,
ASPECT-R (L.D. Alphs, C.A. Bossie, 2015, submitted;
C.A. Bossie, L.D. Alphs, D. Williamson, L. Mao, C.
Kurut, the ASPECT-R Rater Team, 2015, submitted),
which quantifies the pragmatic : explanatory nature of a
study’s design and explores the relevance of the result to
treatment failure, including relapse, hospitalization, and
treatment discontinuation. The findings presented here
support a hypothesis that explanatory designs introduce
features that obscure advantages related to medication
treatment adherence, whereas pragmatic design features
enable identification of these advantages for LAIs that
would be expected in a naturalistic setting for patients
who clinicians would select for this treatment. In fact, the
range of ASPECT-R total scores for the two groups of
studies did not overlap (Table 2).
On the basis of the expected advantage of LAI AP
treatment, it was hypothesized that the ‘Participant
Compliance Assessment’ domain would be the most
differentiating between two groups of studies. Findings
were consistent with this hypothesis (P= 0.005), although
the mean scores for all domains differed significantly
between the two groups.
Several limitations of this work must be considered.
Studies with conventional (typical) depot AP agents were
not well represented (i.e. three studies: Tiihonen et al.,
2006; Zhu et al., 2008; Tiihonen et al., 2011).
Consequently, it is unclear to what degree findings
would translate to work with conventional depot APs.
Nevertheless, Kishimoto et al. (2014) have noted that
studies of first-generation LAIs [fluphenazine (n= 8) and
haloperidol (n= 1)] show a significant benefit for LAI
over oral treatment. Second, only the consensus ratings of
two authors (C.A.B., L.D.A.) who developed the
ASPECT-R were used for this analysis. Consequently,
ASPECT-R ratings found in this study may not be
representative of ratings from individuals less familiar
with the instrument. However, a recently completed
inter-rater reliability assessment with novice, but trained
raters found an interclass correlation of 0.87, which corre-
sponds to an excellent inter-rater reliability (C.A. Bossie,
L.D. Alphs, D. Williamson, L. Mao, C. Kurut, the
ASPECT-R Rater Team, 2015, submitted). Finally, rele-
vant information to fully establish ASPECT-R ratings may
not have been fully documented in the primary reports
used for this study. Lack of access to source documenta-
tion, such as trial protocols, may impact ASPECT-R scores
and the ability to assess all domains accurately.
Criteria for our literature search included a 20-year pub-
lication date range (1 January 1993 to 31 December
2013). However, a recently published study
(PROACTIVE; Buckley et al., 2015) is quite important
and relevant to our research question and requires com-
ment (Buckley et al., 2015). The authors state that their
time to relapse or hospitalization study of patients with
schizophrenia randomized to either a LAI (risperidone) or
an oral AP incorporated both explanatory and pragmatic
Table 2 ASPECT-R individual domain and total scores by study outcome and citation
Participant
eligibility
Intervention
flexibilitya
Medical practice
setting/practitioner
expertisea
Follow-up
intensity/
duration
Primary trial
outcomes
Participant
compliance
assessment Total score
ASPECT-R scores of studies concluding benefit of LAI versus daily oral antipsychotic
Bitter et al. (2013) 5 6 6 6 6 6 35
Grimaldi-Bensouda et al. (2012) 5 6 3 3 6 6 29
Tiihonen et al. (2011) 5 6 6 6 6 6 35
Gaebel et al. (2010) 3 3 2 2 4 4 18
Olivares et al. (2009) 6 6 5 5 6 5 33
Zhu et al. (2008) 5 6 6 6 6 6 35
Tiihonen et al. (2006) 6 6 6 6 6 6 36
ASPECT-R scores of studies concluding no benefit of LAI versus daily oral antipsychotic
Rosenheck et al. (2011) 1 4 0 1 5 2 13
Kane et al. (2010) 3 0 0 0 4 2 9
Macfadden et al. (2010) 4 2.5 1 1 2 2 12.5
Keks et al. (2007) 2 2 0 2 4 3 13
Comparison of ASPECT-R individual domain and total scores in studies concluding benefit versus concluding no benefit of LAI vs. daily oral antipsychotic
Studies finding a benefit of LAIs
(mean ±SD)
5.0 ± 1.0 5.6 ± 1.1 4.9 ±1.7 4.9 ±1.7 5.7 ± 0.8 5.6 ±0.8 31.6 ±6.4
Studies not finding a benefit of
LAIs (mean ±SD)
2.0 ± 1.3 2.1 ± 1.6 0.3 ±0.5 1.0 ±0.8 3.8 ± 1.3 2.3 ±0.5 11.9 ±1.9
P-value 0.015 0.007 0.006 0.009 0.012 0.005 0.007
ASPECT-R, A Study Pragmatic : Explanatory Characterization Tool-Rating; LAI, long-acting injectable.
aThe individual ASPECT-R scores for the domains of ‘intervention flexibility-experimental’ and ‘intervention flexibility-comparison’ as well as for ‘medical setting/practitioner
expertise-experimental’ and ‘medical setting/practitioner expertise-comparison’ were averaged such that one score was included for each of these parameters.
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design features. As such, and similar to the findings of the
four studies in this analysis that found no difference (Keks
et al., 2007; Kane et al., 2010; Macfadden et al., 2010;
Rosenheck et al., 2011), these investigators found no sig-
nificant difference in either time to relapse or hospitaliza-
tion, and add that their study design is similar to several of
these earlier trials. Many of their study design character-
istics leaned strongly toward a more explanatory trial, such
as uniform and frequent monitoring (i.e. every 2-week
office visits) and LAI informed consent treatment
requirements that may have diluted the potential for those
with documented nonadherence to enroll. In their discus-
sion, the authors acknowledge that these explanatory study
design characteristics may have resulted in the enrollment
of patients who are more engaged in their care, with a
reduced inclusion of participants with documented non-
adherence. These types of patients are less likely to stop
taking oral medication, making it more difficult to detect
differences between the LAI and oral treatment.
In conclusion, this research adds to the previous literature
by providing a novel and informative approach that
quantifies the pragmatic : explanatory design of studies
that compare LAI and oral APs for the treatment of
schizophrenia. Previous meta-analytic approaches
applied to these studies are based on study results
without a detailed and quantitative reference to their
specific design and methodological features. The use of
ASPECT-R represents a very different approach by
providing a structured quantification of specific design
elements, without consideration of study results (L.D.
Alphs, C.A. Bossie, 2015, submitted; C.A. Bossie, L.D.
Alphs, D. Williamson, L. Mao, C. Kurut, the ASPECT-R
Rater Team, 2015, submitted). These two distinct
approaches to address the same question are com-
plementary and provide more information than either
approach alone. Although highly controlled studies
remain the gold standard for evidence-based trial designs
to answer most questions in medicine and psychiatry,
pragmatic study design elements are arguably more
valuable for addressing questions such as those related to
real-world populations, practice, and outcomes, especially
when the primary target is enhancing adherence. Their
use can add to the generalizability of available evidence.
Our findings suggest that pragmatic study characteristics
are important in showing the expected advantage of LAI
over daily oral AP treatment in schizophrenia.
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